Mark Baldry Sells 29,159 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) insider Mark Baldry sold 29,159 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $13,121.55. Following the completion of the sale, the insider now owns 94,123 shares of the company’s stock, valued at $42,355.35. The trade was a 23.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

X4 Pharmaceuticals Trading Down 2.0 %

NASDAQ:XFOR opened at $0.48 on Wednesday. The company has a market cap of $82.17 million, a PE ratio of -5.35 and a beta of 0.14. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. X4 Pharmaceuticals, Inc. has a one year low of $0.26 and a one year high of $1.60. The firm has a 50-day moving average of $0.55 and a 200-day moving average of $0.61.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Stifel Nicolaus reduced their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a research note on Tuesday, January 14th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Verition Fund Management LLC purchased a new position in X4 Pharmaceuticals during the third quarter worth about $30,000. SG Americas Securities LLC bought a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth approximately $37,000. XTX Topco Ltd purchased a new position in shares of X4 Pharmaceuticals in the 2nd quarter worth approximately $65,000. Rhumbline Advisers grew its holdings in shares of X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after acquiring an additional 23,831 shares in the last quarter. Finally, Jane Street Group LLC increased its position in shares of X4 Pharmaceuticals by 103.4% during the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock valued at $166,000 after acquiring an additional 126,296 shares during the last quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.